Active ingredient (in each tablet)

Calcium carbonate 1000 mg

Purpose

Antacid

Uses

relieves

heartburn
sour stomach
acid indigestion

Warnings

Ask a doctor or pharmacist before use if you are

now taking a prescription drug. Antacids may interact with certain prescription drugs.

When using this product

do not exceed 7 tablets daily or use the maximum dosage for more than 2 weeks

Keep out of reach of children.

Directions

chew 2 to 3 tablets as symptoms occur

Other information

each tablet contains: calcium 425 mg and magnesium 10 mg
store at 20°-25°C (68°-77°F)

Inactive ingredients

adipic acid, dextrose, FD&C blue #1 aluminum lake, FD&C red #40 aluminum lake, FD&C yellow #5 aluminum lake (tartrazine), FD&C yellow #6 aluminum lake, flavors, maltodextrin, mineral oil, polyethylene glycol, powdered cellulose, talc

Questions? 1-800-719-9260

Principal Display Panel

Compare to the Active Ingredient in Maximum Strength Tums Ultra® Assorted Fruit

CALCIUM ANTACID

TABLETS

ULTRA STRENGTH

ASSORTED FLAVORS

Naturally and Artificially Flavored

Antacid/Calcium Supplement

1,000 mg Calcium Carbonate

Chewable

Calcium Antacid Front Label

Calcium Antacid Back Label

CARE ONE CALCIUM ANTACID
calcium carbonate tablet, chewable

Product Information
Product Type	HUMAN OTC DRUG	Item Code (Source)	NDC:41520-595
Route of Administration	ORAL	DEA Schedule

Active Ingredient/Active Moiety
Ingredient Name	Basis of Strength	Strength
CALCIUM CARBONATE (CARBONATE ION)	CALCIUM CARBONATE	1000mg

Inactive Ingredients
Ingredient Name	Strength
ADIPIC ACID
DEXTROSE
MALTODEXTRIN
MINERAL OIL
POWDERED CELLULOSE
TALC
POLYETHYLENE GLYCOLS

Product Characteristics
Color	YELLOW,GREEN,RED,ORANGE	Score	no score
Shape	ROUND	Size	20mm
Flavor	FRUIT (lime, orange, cherry, lemon)	Imprint Code	L595
Contains

Packaging
#	Item Code	Package Description	Multilevel Packaging
1	NDC:41520-595-23	72 TABLET, CHEWABLE ( TABLET) in 1 BOTTLE	None

Marketing Information
Marketing Category	Application Number or Monograph Citation	Marketing Start Date	Marketing End Date
OTC monograph final	part331	03/01/2004